| 6.86 |
 0.12
|
1.78% | 5,778,803 | Market data is delayed by at least 20 minutes. | ||
| Last | Change | / | % Change | Volume |
|
Exclusive Features |
||
| When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes. |
Or
|
|
|
--/--
Bid/Size |
--/--
Ask/Size |
6.90
Price Open |
||
|
6.74
Previous Close |
6.97
Day High |
6.69
Day Low |
||
|
1.31
Beta (5yr) |
8.00/7/30/10
52wk High/Date |
2.70/5/25/10
52wk Low/Date |
||
|
832.1 Million
Market Capitalization |
121.3 Million
Shares Outstanding |
65.66
Volatility Avg (1 Year) |
||
|
5 Million
Avg Vol (10 day) |
NM
P/E Ratio |
-1.31
EPS (TTM) |
||
|
Arena Pharmaceuticals Inc does not pay dividends. |
||||
Get the following exclusive content at no additional cost with your Scottrade account:
- Standard & Poor's STARS Rating for the featured stock
- Research reports from Reuters and Standard & Poor's
- Market Edge Second Opinion Weekly Report
Arena Pharmaceuticals Inc vs. Peers
| Company | Market Cap | YTD Price Performance |
|
ARNA
Arena Pharmaceuticals Inc |
770.4M | |
|
ABT
Abbott Laboratories |
78.3B |
Company Background
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's advanced drug candidate is lorcaserin hydrochloride (lorcaserin), for weight management, which has completed a pivotal Phase III clinical trial program. In December 2009, it submitted a new drug application (NDA), for lorcaserin to the United States Food and Drug Administration (FDA), for regulatory approval. In addition to lorcaserin, its internal development programs include APD791, APD916 and APD811, all of which are oral drug candidates. APD791 is a selective inverse agonist of the serotonin IIA receptor intended for the treatment of arterial thrombosis and other related conditions, and it has completed Phase Ia and Phase Ib clinical trials.
Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC
Online market and limit stock trades are just $7 for stocks priced $1 and above.
Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.
Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade branch office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.
Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.
Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.
Options involve risk and are not suitable for all investors. Detailed information on our policies and the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, and by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.
Market volatility, volume, and system availability may impact account access and trade execution.
Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.